PL 2258

Drug Profile

PL 2258

Alternative Names: PL2258; PL2258-Merck; PL2258B

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Merck & Co; Piramal Healthcare
  • Developer Piramal Enterprises
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Insulin-like growth factor-I receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in India (PO)
  • 01 Sep 2014 Piramal suspends phase I trial in Solid tumours (Late-stage disease, Second-line or greater therapy) in India (NCT01779336)
  • 01 Dec 2012 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line or greater therapy) in India (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top